A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Trial data suggest a JAK inhibitor beats the leading biologic ...

This healthcare giant is a top pick for growth and dividend investors.

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost management strategies.

AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income. The JEPQ ETF employs a covered-call ...

Experts say hair loss treatments such as Rogaine and Propecia are effective and widely available. However, various treatments ...

AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies ...

AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected. AbbVie's valuation and dividend program seal the deal.

products industries. Its key products include anti-inflammation drug Stelara, multiple myeloma and light chain amyloidosis drug Darzalex, and nasal spray depression treatment Spravato. Analyst David ...